Corrigendum to "Structure guided development of potent piperazine-derived hydroxamic acid inhibitors targeting falcilysin" [Bioorg. Med. Chem. Lett. 32 (2021) 127683].
作者信息
Kahlon Gulbag, Lira Rogelio, Masvlov Nikolay, Pompa Emmett, Brar Nimrat, Eagon Scott, Anderson Marc O, Andaya Armann, Chance Jeff P, Fejzic Hannah, Keniston Aaron, Huynh Ngoc, Celis Nohemy, Vidal Brian, Trieu Nicholas, Rodriguez Paulina, Mallari Jeremy P
机构信息
Department of Chemistry and Biochemistry, California State University, San Bernardino, USA.
Department of Chemistry and Biochemistry, California Polytechnic State University, San Luis Obispo, USA.
出版信息
Bioorg Med Chem Lett. 2021 Apr 1;37:127836. doi: 10.1016/j.bmcl.2021.127836. Epub 2021 Feb 13.
PMID:33588181
Abstract
摘要
相似文献
1
Corrigendum to "Structure guided development of potent piperazine-derived hydroxamic acid inhibitors targeting falcilysin" [Bioorg. Med. Chem. Lett. 32 (2021) 127683].《针对falcilysin的强效哌嗪衍生异羟肟酸抑制剂的结构导向开发》的勘误[《生物有机与药物化学快报》32 (2021) 127683]
Bioorg Med Chem Lett. 2021 Apr 1;37:127836. doi: 10.1016/j.bmcl.2021.127836. Epub 2021 Feb 13.
2
Corrigendum to "Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase" [Bioorg. Med. Chem. Lett. 29 (2019) 1918-1921].
Bioorg Med Chem Lett. 2019 Sep 1;29(17):2525. doi: 10.1016/j.bmcl.2019.07.032. Epub 2019 Jul 25.
3
Corrigendum to "Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay" [Bioorg. Med. Chem. Lett. 25 (2015) 2505-2509].《使用快速PK筛选测定法评估二氟唾液酸前药（强效病毒神经氨酸酶抑制剂）的口服生物利用度》的勘误[《生物有机与药物化学快报》25 (2015) 2505 - 2509]
Bioorg Med Chem Lett. 2016 Jul 2. doi: 10.1016/j.bmcl.2016.06.068.
4
Corrigendum to "Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors" [Bioorg. Med. Chem. Lett. 60 (2022) 128549].
Bioorg Med Chem Lett. 2022 Sep 15;72:128856. doi: 10.1016/j.bmcl.2022.128856. Epub 2022 Jun 18.
5
Development of piperazine-based hydroxamic acid inhibitors against falcilysin, an essential malarial protease.哌嗪基羟肟酸类抑制剂对抗裂殖体，一种疟原虫必需的蛋白酶的开发。
Bioorg Med Chem Lett. 2018 Jun 1;28(10):1846-1848. doi: 10.1016/j.bmcl.2018.04.010. Epub 2018 Apr 19.
6
Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675].
Bioorg Med Chem Lett. 2020 Jan 15;30(2):126771. doi: 10.1016/j.bmcl.2019.126771. Epub 2019 Dec 16.
7
Corrigendum to "Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core" [Bioorg. Med. Chem. Lett. 26 (2016) 5399-5402].
Bioorg Med Chem Lett. 2020 Feb 15;30(4):126931. doi: 10.1016/j.bmcl.2019.126931. Epub 2020 Jan 2.
8
Corrigendum to "Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists" [Bioorg. Med. Chem. Lett. 24/5 (2014) 1426-1431].《新型苯甲酰胺衍生物作为高效的Smoothened拮抗剂的合成及生物学评价》的勘误[《生物有机与药物化学快报》24/5 (2014) 1426 - 1431]
Bioorg Med Chem Lett. 2016 Sep 15;26(18):4558. doi: 10.1016/j.bmcl.2015.06.051. Epub 2016 Aug 16.
9
Corrigendum to "Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research" [Bioorg. Med. Chem. Lett. 29 (2019) 2016-2024].
Bioorg Med Chem Lett. 2021 Aug 1;45:128140. doi: 10.1016/j.bmcl.2021.128140. Epub 2021 May 27.
10
Corrigendum to "Investigation of biaryl heterocycles as inhibitors of Wee1 kinase" [Bioorg. Med. Chem. Lett. 29 (2019) 1481-1486].《关于“作为Wee1激酶抑制剂的联芳基杂环的研究”的勘误》[《生物有机与药物化学快报》29 (2019) 1481 - 1486]
Bioorg Med Chem Lett. 2020 Feb 15;30(4):126895. doi: 10.1016/j.bmcl.2019.126895. Epub 2020 Jan 8.
Zotero 插件